Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We describe a case of a patient from Far North Queensland, Australia, with life-threatening hepatotoxicity caused by ipilimumab induced immune-related adverse events (irAEs). Our patient presented with non-specific symptoms including malaise, lethargy and fevers. Her work up revealed acute hepatitis, which was presumed to be related to ipilimumab treatment for her metastatic melanoma. Causality for ipilimumab was assessed with the CIOMS scale (Council for International Organizations of Medical Sciences) and provided a causality level of ‘highly probable’ (score +9). She was started on methylprednisolone as per guidelines for ipilimumab induced irAEs. On the second day of treatment her transaminases enzymes unexpectedly rose several hundred times. Investigations for other causes of acute hepatitis including abdominal imaging were negative. She was started up front on equine antithymocyte globulin, mycophenolate moefetil and continued on methylprednisolone. She recovered clinically and biochemically in 2 weeks and continues to remain well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Cited by
RUCAM in Drug and Herb Induced Liver Injury: The Update
Danan, G., & Teschke, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010014 · Cited by 729
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Peeraphatdit, T. (., Wang, J., Odenwald, M. A., Hu, S., Hart, J., & Charlton, M. R. (2020) · Hepatology · doi:10.1002/hep.31227 · Cited by 264
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0245 · Cited by 191
Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119
“ATGAM has been successfully used to treat at least two cases of severe ipilimumab-induced hepatotoxicity (Chmiel et al, 2011; Ahmed et al, 2015).”
Metadata
- Authors
- Ahmed, T., Pandey, R., Shah, B., & Black, J.
- Venue
- BMJ Case Reports
- Publisher
- BMJ
- Published
- 2015-07-14
- Volume
- 2015
- Pages
- bcr2014208102
- ISSN
- 1757-790X (ISSN-L)
- OpenAlex
- W1833228626
- Cited by
- 50
- References
- 2
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. https://app.cochat.ai/papers/10.1136/bcr-2014-208102
- The paper
- Ahmed, T., Pandey, R., Shah, B., & Black, J. (2015). Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Reports. https://doi.org/10.1136/bcr-2014-208102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.